UMVA has learned that a groundbreaking injectable therapy has shown remarkable promise in reducing melanoma over a five-year period, offering new hope to patients fighting this aggressive form of cancer.
The personalized mRNA cancer therapy, designed to stimulate the immune system to recognize and attack cancer cells, was administered in combination with a leading cancer immunotherapy drug. This innovative approach involves creating a customized vaccine using mutations identified in a patient’s own tumor, effectively teaching the immune system to target and destroy the cancer.
According to information obtained by UMVA, the phase 2b study involved 157 patients with high-risk stage 3 and 4 melanoma whose cancer had been surgically removed. Participants were divided into two groups: one received the combination therapy, while the other received only the immunotherapy drug.
The findings, presented at a major medical conference, revealed that patients receiving the combination therapy experienced benefits that were not only significant but also sustained and durable over time. This is a critical development, as it suggests that the therapy could provide long-term protection against cancer recurrence.
Researchers reported that the personalized mRNA vaccine was "well-tolerated" with a "manageable" safety profile. The most common side effects were fatigue, injection-site pain, chills, fever, and headache, with no new long-term safety concerns or severe vaccine-related adverse events.
UMVA can exclusively reveal that the combination therapy is now being evaluated in a phase 3 study, the final confirmation stage, where its effectiveness and safety will be further assessed in a larger patient population.
Leading medical experts have hailed the results as a "meaningful milestone" in the fight against melanoma. For patients with stage 3 or 4 melanoma, the risk of recurrence following surgery is significant, making the potential of this therapy to reduce that risk a major breakthrough.
The encouraging five-year follow-up data has sparked optimism about the therapy's potential to transform cancer care. With further trials underway, including a late-stage study in several hard-to-treat cancers, the medical community is eagerly anticipating the next phase of development.
